Medical Firm Grounded: DEA Yanks Registration Over Lax Checks
Published Date: 1/27/2026
Notice
Summary
Allied Medical Products, Inc. lost its DEA registration because it didn’t properly check its customers before selling controlled substances and let someone else use its account. This means Allied Medical can no longer legally distribute these drugs, effective immediately. The decision protects public safety and sends a clear message about following the rules.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked — No Drug Distribution
Allied Medical Products, Inc. (DEA Certificate No. RA0235146) had its DEA registration revoked, so it cannot legally distribute controlled substances after February 26, 2026. The revocation follows a finding that Allied failed to perform required customer due diligence and allowed another entity to use its purchasing account.
Pending DEA Applications Denied in California
The Agency denied any pending applications by Allied Medical Products, Inc. to renew or modify its DEA registration, as well as any other pending application for additional registration in California, effective February 26, 2026. Those applications will not proceed while the denial stands.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2026-01493, Cessation of Trustee Terms
Two trustees at the Institute of American Indian and Alaska Native Culture and Arts Development will finish their terms on May 19, 2026. This means new trustees will need to step up soon to keep the board strong and creative. If you’re involved or interested, mark your calendar and get ready for some fresh faces and ideas!
Next: 2026-01498, Complete Care Pharmacy, LLC; Decision and Order
Complete Care Pharmacy in New Mexico lost its DEA license because its owner filled 26 drug prescriptions without having the legal authority to do so. This means the pharmacy can no longer handle controlled substances, impacting its business immediately. Anyone relying on this pharmacy for such medications will need to find a new provider fast.